The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $48.38 in the prior trading day, Soleno Therapeutics Inc (NASDAQ: SLNO) closed at $47.85, down -1.10%. In other words, the price has decreased by -$1.10 from its previous closing price. On the day, 2.31 million shares were traded. SLNO stock price reached its highest trading level at $49.315 during the session, while it also had its lowest trading level at $47.46.
Ratios:
Our goal is to gain a better understanding of SLNO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.88 and its Current Ratio is at 16.08. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In the most recent recommendation for this company, Wolfe Research on November 18, 2025, initiated with a Outperform rating and assigned the stock a target price of $75. On October 07, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $125. On August 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $123.Wells Fargo initiated its Overweight rating on August 20, 2025, with a $123 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Abingworth Bioventures VII LP bought 1,347,522 shares for $82.15 per share.
Hirano Patricia C sold 3,830 shares of SLNO for $316,971 on Jul 01 ’25. The insider now owns 13,206 shares after completing the transaction at $82.76 per share. On Jul 01 ’25, another insider, PATRICIA HIRANO, who serves as the Officer of the company, bought 3,830 shares for $82.76 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLNO now has a Market Capitalization of 2570024448 and an Enterprise Value of 2123753728. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.05 while its Price-to-Book (P/B) ratio in mrq is 5.19. Its current Enterprise Value per Revenue stands at 21.523 whereas that against EBITDA is -25.818.
Stock Price History:
The Beta on a monthly basis for SLNO is -3.11, which has changed by 0.06463456 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, SLNO has reached a high of $90.32, while it has fallen to a 52-week low of $41.50. The 50-Day Moving Average of the stock is -12.93%, while the 200-Day Moving Average is calculated to be -28.81%.
Shares Statistics:
The stock has traded on average 1.89M shares per day over the past 3-months and 1553580 shares per day over the last 10 days, according to various share statistics. A total of 53.70M shares are outstanding, with a floating share count of 49.27M. Insiders hold about 8.30% of the company’s shares, while institutions hold 117.16% stake in the company. Shares short for SLNO as of 1764288000 were 9093766 with a Short Ratio of 4.82, compared to 1761868800 on 8484772. Therefore, it implies a Short% of Shares Outstanding of 9093766 and a Short% of Float of 19.299999.
Earnings Estimates
As of right now, 13.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.68, with high estimates of $1.08 and low estimates of $0.23.
Analysts are recommending an EPS of between $0.74 and -$0.24 for the fiscal current year, implying an average EPS of $0.19. EPS for the following year is $4.11, with 13.0 analysts recommending between $5.78 and $1.78.
Revenue Estimates
For the next quarter, 11 analysts are estimating revenue of $90.17M. There is a high estimate of $108.18M for the next quarter, whereas the lowest estimate is $73.8M. Based on 11 analysts’ estimates, the company’s revenue will be $465.69M in the next fiscal year. The high estimate is $563.14M and the low estimate is $351.6M.
